vs

Side-by-side financial comparison of Princeton Bancorp, Inc. (BPRN) and NEKTAR THERAPEUTICS (NKTR). Click either name above to swap in a different company.

NEKTAR THERAPEUTICS is the larger business by last-quarter revenue ($21.8M vs $20.7M, roughly 1.1× Princeton Bancorp, Inc.). Princeton Bancorp, Inc. runs the higher net margin — 29.3% vs -165.4%, a 194.7% gap on every dollar of revenue. On growth, Princeton Bancorp, Inc. posted the faster year-over-year revenue change (3.6% vs -25.3%). Princeton Bancorp, Inc. produced more free cash flow last quarter ($20.6M vs $-65.0M). Over the past eight quarters, Princeton Bancorp, Inc.'s revenue compounded faster (9.1% CAGR vs 0.4%).

Princeton Bancorp, Inc. is a U.S.-based bank holding company operating through its community banking subsidiary. It offers retail and commercial banking products including deposit accounts, small business loans, consumer loans, mortgages and wealth management services, primarily serving clients across New Jersey and the U.S. mid-Atlantic region.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

BPRN vs NKTR — Head-to-Head

Bigger by revenue
NKTR
NKTR
1.1× larger
NKTR
$21.8M
$20.7M
BPRN
Growing faster (revenue YoY)
BPRN
BPRN
+28.8% gap
BPRN
3.6%
-25.3%
NKTR
Higher net margin
BPRN
BPRN
194.7% more per $
BPRN
29.3%
-165.4%
NKTR
More free cash flow
BPRN
BPRN
$85.6M more FCF
BPRN
$20.6M
$-65.0M
NKTR
Faster 2-yr revenue CAGR
BPRN
BPRN
Annualised
BPRN
9.1%
0.4%
NKTR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BPRN
BPRN
NKTR
NKTR
Revenue
$20.7M
$21.8M
Net Profit
$6.1M
$-36.1M
Gross Margin
Operating Margin
38.2%
-126.9%
Net Margin
29.3%
-165.4%
Revenue YoY
3.6%
-25.3%
Net Profit YoY
16.3%
-596.9%
EPS (diluted)
$0.89
$-4.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BPRN
BPRN
NKTR
NKTR
Q4 25
$20.7M
$21.8M
Q3 25
$21.5M
$11.8M
Q2 25
$21.1M
$11.2M
Q1 25
$20.9M
$10.5M
Q4 24
$20.0M
$29.2M
Q3 24
$19.2M
$24.1M
Q2 24
$18.1M
$23.5M
Q1 24
$17.4M
$21.6M
Net Profit
BPRN
BPRN
NKTR
NKTR
Q4 25
$6.1M
$-36.1M
Q3 25
$6.5M
$-35.5M
Q2 25
$688.0K
$-41.6M
Q1 25
$5.4M
$-50.9M
Q4 24
$5.2M
$7.3M
Q3 24
$-4.5M
$-37.1M
Q2 24
$5.1M
$-52.4M
Q1 24
$4.3M
$-36.8M
Gross Margin
BPRN
BPRN
NKTR
NKTR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Q1 24
60.6%
Operating Margin
BPRN
BPRN
NKTR
NKTR
Q4 25
38.2%
-126.9%
Q3 25
38.5%
-268.6%
Q2 25
2.8%
-324.2%
Q1 25
32.9%
-425.8%
Q4 24
34.0%
49.2%
Q3 24
-29.1%
-142.4%
Q2 24
34.1%
-211.9%
Q1 24
31.0%
-163.7%
Net Margin
BPRN
BPRN
NKTR
NKTR
Q4 25
29.3%
-165.4%
Q3 25
30.0%
-301.3%
Q2 25
3.3%
-372.2%
Q1 25
25.7%
-486.4%
Q4 24
26.1%
24.9%
Q3 24
-23.3%
-153.6%
Q2 24
28.4%
-222.9%
Q1 24
24.9%
-170.1%
EPS (diluted)
BPRN
BPRN
NKTR
NKTR
Q4 25
$0.89
$-4.67
Q3 25
$0.95
$-1.87
Q2 25
$0.10
$-2.95
Q1 25
$0.77
$-0.24
Q4 24
$0.75
$-2.07
Q3 24
$-0.68
$-2.66
Q2 24
$0.80
$-3.76
Q1 24
$0.68
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BPRN
BPRN
NKTR
NKTR
Cash + ST InvestmentsLiquidity on hand
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$270.7M
$89.8M
Total Assets
$2.3B
$280.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BPRN
BPRN
NKTR
NKTR
Q4 25
$15.1M
Q3 25
$41.0M
Q2 25
$43.0M
Q1 25
$38.9M
Q4 24
$44.3M
Q3 24
$30.1M
Q2 24
$27.9M
Q1 24
$48.6M
Total Debt
BPRN
BPRN
NKTR
NKTR
Q4 25
Q3 25
$0
Q2 25
$10.0M
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BPRN
BPRN
NKTR
NKTR
Q4 25
$270.7M
$89.8M
Q3 25
$266.6M
$85.1M
Q2 25
$261.9M
$-24.2M
Q1 25
$267.0M
$13.7M
Q4 24
$262.0M
$60.7M
Q3 24
$261.5M
$48.9M
Q2 24
$244.8M
$79.7M
Q1 24
$241.8M
$126.7M
Total Assets
BPRN
BPRN
NKTR
NKTR
Q4 25
$2.3B
$280.4M
Q3 25
$2.2B
$301.3M
Q2 25
$2.2B
$207.5M
Q1 25
$2.3B
$256.2M
Q4 24
$2.3B
$303.9M
Q3 24
$2.4B
$308.0M
Q2 24
$2.0B
$343.3M
Q1 24
$2.0B
$396.0M
Debt / Equity
BPRN
BPRN
NKTR
NKTR
Q4 25
Q3 25
0.00×
Q2 25
0.04×
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BPRN
BPRN
NKTR
NKTR
Operating Cash FlowLast quarter
$21.5M
$-65.0M
Free Cash FlowOCF − Capex
$20.6M
$-65.0M
FCF MarginFCF / Revenue
99.3%
-298.0%
Capex IntensityCapex / Revenue
4.3%
0.1%
Cash ConversionOCF / Net Profit
3.54×
TTM Free Cash FlowTrailing 4 quarters
$29.2M
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BPRN
BPRN
NKTR
NKTR
Q4 25
$21.5M
$-65.0M
Q3 25
$4.9M
$-48.8M
Q2 25
$3.1M
$-45.7M
Q1 25
$1.3M
$-49.1M
Q4 24
$14.7M
$-46.2M
Q3 24
$1.2M
$-43.9M
Q2 24
$4.3M
$-37.7M
Q1 24
$4.8M
$-47.9M
Free Cash Flow
BPRN
BPRN
NKTR
NKTR
Q4 25
$20.6M
$-65.0M
Q3 25
$4.7M
$-48.9M
Q2 25
$2.9M
$-45.8M
Q1 25
$1.1M
$-49.1M
Q4 24
$13.2M
$-46.6M
Q3 24
$766.0K
$-44.6M
Q2 24
$3.9M
$-37.9M
Q1 24
$4.8M
$-48.0M
FCF Margin
BPRN
BPRN
NKTR
NKTR
Q4 25
99.3%
-298.0%
Q3 25
21.6%
-414.5%
Q2 25
13.7%
-409.6%
Q1 25
5.0%
-469.0%
Q4 24
65.9%
-159.9%
Q3 24
4.0%
-184.9%
Q2 24
21.8%
-161.3%
Q1 24
27.3%
-222.0%
Capex Intensity
BPRN
BPRN
NKTR
NKTR
Q4 25
4.3%
0.1%
Q3 25
1.1%
1.0%
Q2 25
1.2%
0.3%
Q1 25
1.0%
0.0%
Q4 24
7.6%
1.6%
Q3 24
2.2%
2.8%
Q2 24
2.1%
0.8%
Q1 24
0.4%
0.7%
Cash Conversion
BPRN
BPRN
NKTR
NKTR
Q4 25
3.54×
Q3 25
0.76×
Q2 25
4.57×
Q1 25
0.23×
Q4 24
2.82×
-6.36×
Q3 24
Q2 24
0.84×
Q1 24
1.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons